Publication
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
Authors not recorded
JCO Precis Oncol2023PMID 37053535PMC10309549stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Neoplasmcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneGNA11civic_curation1.00
- geneNF1civic_curation1.00
- variantGNA11 Q209Lcivic_curation1.00
- variantNF1 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37053535
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| GNA11 Q209L + NF1 MutationNF1GNA111 | ||||||||
| Trametinib | Malignant NeoplasmALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID12027In this phase 2 clinical trial, 50 patients were treated with trametinib, a MEK1/2 inhibitor. Among them, 46 had tumours harbouring NF1 mutations (S1 protocol), while 4 had non-uveal melanomas harbour… (full text at CIViC) PMID 37053535 · Wisinski et al., 2023 · Open in CIViC | civic |